Form 483

Andapharm, LLC Form 483, 2012-02-07

FDA issued a Form 483 to Andapharm, LLC on 2012-02-07 with 7 public-safe observations.

483· Form 483 issued7 observations

Andapharm, LLC · Fort Lauderdale, United States · Issued February 7, 2012

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

7 Feb 2012
21 CFR 211.25(a)

Training--operations, GMPs, written procedures

Cited by Ileana Barreto-Pettit

7 Feb 2012
21 CFR 211.42(c)

Defined areas of adequate size for operations

Cited by Ileana Barreto-Pettit

7 Feb 2012
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Ileana Barreto-Pettit

7 Feb 2012
21 CFR 211.166(a)

Written program not followed

Cited by Ileana Barreto-Pettit

7 Feb 2012
21 CFR 211.166(a)(3)

Valid stability test methods

Cited by Ileana Barreto-Pettit

Inspected site

ALAndapharm, LLCFort Lauderdale, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.198(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere